Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting by Hanekamp, D et al.
Applicability and reproducibility of acute myeloid leukaemia
stem cell assessment in a multi-centre setting
Diana Hanekamp,1
Alexander N. Snel,1 Angele Kelder,1
Willemijn J. Scholten,1 Naeem Khan,2
Marlen Metzner,3 Maria Irno-Consalvo,4
Mayumi Sugita,5 Anja de Jong,6
Sjoerd Oude Alink,7 Harrie Eidhof,8
Miriam Wilhelm,9
Michaela Feuring-Buske,9
Jennichjen Slomp,8 Vincent H. J. van
der Velden,7 Edwin Sonneveld,6
Monica Guzman,5 Gail J. Roboz,5
Francesco Buccisano,4 Paresh Vyas,3
Sylvie Freeman,2 Costa Bachas,1
Gert J. Ossenkoppele,1
Gerrit J. Schuurhuis1 and
Jacqueline Cloos1
1Department of Hematology, Amsterdam
UMC, Vrije Universiteit Amsterdam,
Cancer Center Amsterdam, Amsterdam,
the Netherlands, 2Institute of Immunology
and Immunotherapy, Department of
Clinical Immunology, University of
Birmingham, Birmingham, United
Kingdom, 3Medical Research Council
Molecular Hematology Unit, Oxford Centre
for Hematology, Oxford BRC, University of
Oxford and Oxford University Hospitals
National Health Service Trust, Oxford,
United Kingdom, 4Department of
Biomedicine and Prevention, University of
Rome Tor Vergata, Rome, Italy, 5Division
of Hematology and Oncology, Department
of Medicine, Weill Cornell Medical College,
New York, NY, USA, 6Dutch Childhood
Oncology Group, Utrecht, the Netherlands,
7Department of Immunology, Laboratory
Medical Immunology, Erasmus MC,
University Medical Center Rotterdam,
Rotterdam, the Netherlands, 8Department
of Clinical Chemistry, Medisch Spectrum
Twente/Medlon, Enschede, the Netherlands,
and 9Department of Internal Medicine III,
University Hospital Ulm, Ulm, Germany
Summary
Leukaemic stem cells (LSC) have been experimentally defined as the leukae-
mia-propagating population and are thought to be the cellular reservoir of
relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements
are warranted to facilitate accurate risk stratification. Previously, we pub-
lished the composition of a one-tube flow cytometric assay, characterised
by the presence of 13 important membrane markers for LSC detection.
Here we present the validation experiments of the assay in several large
AML research centres, both in Europe and the United States. Variability
within instruments and sample processing showed high correlations
between different instruments (Rpearson > 091, P < 0001). Multi-centre
testing introduced variation in reported LSC percentages but was found to
be below the clinical relevant threshold. Clear gating protocols resulted in
all laboratories being able to perform LSC assessment of the validation set.
Participating centres were nearly unanimously able to distinguish LSChigh
(>003% LSC) from LSClow (<003% LSC) despite inter-laboratory varia-
tion in reported LSC percentages. This study proves that the LSC assay is
highly reproducible. These results together with the high prognostic impact
of LSC load at diagnosis in AML patients render the one-tube LSC assess-
ment a good marker for future risk classification.
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Acute myeloid leukaemia (AML) is a heterogeneous group of
diseases, with the shared feature of proliferation of immature
myeloid blasts in the bone marrow and blood. The classifica-
tion of AML has changed dramatically over the last decades,
and is mainly based on the chromosomal abnormalities and
gene mutations underlying each individual’s disease.1 Despite
this advancement, risk classification remains suboptimal as a
proportion of patients will relapse regardless of the absence
of poor-risk factors at diagnosis. Improved detection of mea-
surable residual disease (MRD) during therapy by
immunophenotypic and molecular methods has shown low
levels of persisting disease in patients in morphologic remis-
sion,2 essential for further therapy choices. This MRD com-
partment presumably encompasses leukaemic stem cells
(LSCs). LSCs are pivotal for underlying leukaemia propaga-
tion, therapy resistance and as a cellular reservoir of
relapse.3-5 Recent studies have correlated high LSC frequen-
cies at the time of diagnosis with the presence of MRD and
subsequent poor prognosis.6,7 The implementation of LSC
measurements in the clinic is therefore instrumental for risk
stratification and facilitating the selection of appropriate
treatment protocols.8,9
Several studies identified LSCs by (cyto)genetic and func-
tional characteristics.4,9,10 Apart from these assays, LSCs can
be immunophenotypically identified based on the principle
that LSC can aberrantly express antigens. These flow cyto-
metric assays can easily be implemented in most AML diag-
nostic workups. Although different cellular compartments are
shown to possibly contain leukaemia-initiating cells,9,11 the
CD34+CD3– compartment is the most established.6,12,13 The
use of an antibody panel with CD34 and CD38 has therefore
been the basis of many studies, discriminating the
CD34+CD38–cell fraction, which contains both LSCs and
normal haematopoietic stem cells (HSCs), from other cells.
For optimal discrimination between LSCs and HSCs, mul-
tiple markers were identified, highlighting the heterogeneity
of AML LSCs.6,7 We previously tested many of the proposed
LSC markers in a large cohort of AML patients and selected
those which showed the best distinction between HSC and
LSC and, moreover, identified the highest LSC burden.14
After omitting redundant markers, 13 markers (i.e.
CLEC12A, TIM-3, CD7, CD11b, CD22, CD56, CD33,
CD45RA, CD123, CD44 and backbone markers CD34, CD38,
CD45) remained necessary for correct identification. This
panel of markers was arranged in a single eight-colour flow
cytometry antibody panel, combining the first six markers
together in one fluorescence channel, hereinafter referred to
as the ‘Combi’ channel, with the potential to be easily imple-
mented in other laboratories.14
Medical laboratory assays are essential to support clini-
cians to provide optimal treatment choices for patients;
hence their results and reports should be of the best achiev-
able quality. Research in improving these assays is ongoing,
but is also directed towards standardisation.15,16 to facilitate
multi-institutional collaborations.
Here we evaluated the technical and analytical feasibility
of the eight-colour LSC single tube assay, as well as standard-
isation of the process. The study is conducted in several large
research centres both in Europe and the United States, with
extensive flow cytometry experience, but not with the
assessed LSC assay. We show that limited training leads to
highly concordant results, allowing other centres to indepen-
dently validate the clinical utility of LSC testing in AML.
These results, together with the high prognostic impact of
the LSC load at AML diagnosis, render the one-tube LSC
assessment a good marker for future risk classification.
Materials and methods
Instruments, setups and samples
The instruments used are listed in Table SI. We previously
described the setup of flow cytometers, as based on EuroFlow
instructions.15,17 Sample information and details regarding
harmonisation of all machines are described in supplemental
materials and methods.
Study setup
A schematic overview of the study setup is shown in Fig 1 and
described in detail in the supplementary text. In short, three
cryopreserved diagnosis samples were used to evaluate inter-
instrument variance and four cryopreserved diagnosis samples
were used for inter-laboratory processing. Gating was trained
on these latter four samples, and validated in 10 FCS files of
representative diagnosis AML samples as listed in Table I.
D. Hanekamp et al.
2 ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd
Statistics
All results showed complete gating strategy, listing the num-
ber of events for all relevant populations (lymphocytes,
(CD34+) blasts, CD34+CD38–, LSC and HSC). LSC percent-
ages ≥003% was classified as LSChigh or LSClow <003%.6,16
Since percentages found in LSClow patients are low, variances
calculated as a coefficient of variation are high. 05 log was
considered as acceptable error with limited effect on prog-
nostic value (Figure S1). Variation was calculated using the
Excel function VAR.P. Pearson correlation coefficients were
calculated when reported percentages were compared
between laboratories or machines.
Results
Central site inter-instrument processing
To evaluate the influence of different flow cytometers, the
assay was first assessed on different platforms at the central
site. Expression plots of the total blast population and
CD34+ blast subpopulation of two representative samples
measured on BD LSRFortessa and BC Gallios EX were com-
pared to BD FACSCanto II. See Fig 2. Lymphocyte and LSC
percentages were analysed in all samples and showed a high
correlation, with results on BD FACSCanto II Fig 2C.
Training
FCS files generated at central site with analysis by six research-
ers from central site. Gating reproducibility within the
trained team at the central site was evaluated by having six
researchers perform LSC assessments on FCS files, generated
at central site (n = 4). See Fig 3 and Figure S2. Since LSCs
are heterogeneous in marker expression, the gating of all
individual markers was analysed (Table SIV). The largest
variance was found for LSCs gated positive for Combi (mean
27*106, range 00–97*106). Without prior knowledge of
inclusion of a CD34– patient,18 all researchers from the cen-
tral site were able to identify this CD34– sample (T3).
FCS files generated at local sites with analysis by one researcher
from central site. The same set of cryopreserved samples
were sent to all participating laboratories, accompanied by a
protocol describing flow cytometer setup (see supplemental
text). Generated FCS files were uploaded by the local sites to
a designated repository and checked by one researcher from
the central site. Percentages of LSC were analysed in all sam-
ples Fig 3, Figure S3 and Table SV). While there was varia-
tion in the number of WBCs measured (T1 mean 1 551 352
events, range 460 484–4 538 067; T2 mean 2 137 499 events,
range 475 915–3 153 669; T3 mean 1 807 224 events, range
548 304–4 218 299; T4 mean 1 318 815 events, range
478 873–3 808 045), measurements were overall highly com-
parable. Representative expression plots of the total blast
population and expression plots of the CD34+ blast subpop-
ulation of sample T2 show a high resemblance between dif-
ferent local sites (Figure S2). Analysis performed by one
researcher from the central site resulted in LSC percentages
resembling those found in the analysis of files generated
within the central site Fig 3. Sample T1 from Laboratory 4
contained 295 370 WBC and could therefore not be anal-
ysed.
FCS files generated at local sites with analysis from local
site. The participating centres were asked for analysis of the
files using the advised gating strategy (see supplemental data
1). Analyses were uploaded to the repository and reviewed
by the central site. When gating could evidently be optimised
(i.e. WBC gate included debris), feedback was sent to the
local site and analysis could be revised. An average of 19
(range 1–3) analysis rounds were needed to come to final
gating results (two laboratories did not need feedback, four
laboratories needed feedback once, while one laboratory
needed feedback twice). Results reported by the local sites
showed more variability (especially in sample T3 and T4),
compared to analyses within the central site (Fig 3, Figure S3
and corresponding Table SVI). In all samples, the largest
variation was found in percentages CD44+ LSC (mean
00003621%, range 00000016–00008108%). In conclu-
sion, variance mostly results from data analysis, not data
collection.
Fig 1. Schematic overview of study setup. The study can be divided
into four parts: (A) pre-analysis by the central site, (B) analysis of four
initial samples by six researchers of the central site and participating
centres (C) identification of critical gating steps and (D) the validation
of both the coordinating centre and the participating centres.
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Critical steps in gating strategy
As a consequence of training the participating centres, a num-
ber of critical steps in the gating strategy were elucidated.
1. Exact gating of WBC compartment. Since the burden of
LSC is presented as a percentage of the complete WBC
load, correct gating of this population is critical. However,
gating for WBCs was not described. Furthermore, as no
live-dead marker is included in the stem cell tube, gating
for viable WBC versus debris is solely based on scatter
properties. Therefore, it is recommended to start with gat-
ing the lymphocytes in a CD45/SSC plot. Since lympho-
cytes are low in side- and forward-scatter properties, they
can act as a starting point for the WBC gate (Figure S4A).
2. Discriminating CD34+ blasts from CD34– blasts. Leukaemic
blasts can differ in CD34 expression, and gating of CD34+
blasts can therefore be challenged by CD34dim blasts – the
CD34/CD38 plot can be illustrative (Figure S4B). After gat-
ing LSC and HSC, the gating strategy supports so-called
back-gating. Both LSC and HSC often present as clusters in
SSC/FSC, CD45/SSC and CD34/SSC plots. Scattered LSC (or
HSC) events low in the CD34+ gate therefore lead to nar-
rowing of the CD34gate (Figure S4C).
All tips for optimal gating were reported to all laboratories
before the validation step was initiated.
Validation
Additional FCS files generated at central site with analysis by research-
ers from central site. To evaluate the reproducibility of LSC
analysis in clinical practice, ten additional representative diag-
nostic FSC files were selected for analysis. Of these samples,
four were LSChigh (V5, V7, V8 and V10), five were LSClow (V1,
V2, V3, V4, V6, V9), of which one was CD34– (V1). Two sam-
ples were around the cut-off (V5 LSChigh, V6 LSClow). Results
similar to routine practice were reported: which includes gat-
ing of all LSC markers (i.e. CD33, CD44, CD123, CD45RA and
Combi) separately and selecting the best marker to ultimately
report as LSC load (Figure S5A, detailed in Table I. As LSCs
are frequently covered by more than one LSC marker, the
selection of a different marker did not always result in identifi-
cation of a distinct different population (see supplemental gat-
ing strategy for examples). Discrimination between high
(≥003%) and low (<003%) LSC load was concurrent among
all researchers in 13/14 samples (93%). Sample V3 showed dis-
cordance between the researchers, as one researcher included
CD45high cells as leukaemic blasts and CD34+CD38– cells with
higher scatter properties as LSC, in absence of LSC markers.
The selected ‘best’ marker (Table SVII) showed high resem-
blance (i.e. 5/6 or 6/6 researchers chose the same marker) in
some of the samples (6/14; 43%), and lower resemblance (i.e.
3–4 of the six researchers chose the same marker) in the other
samples (8/14; 57%). CD45RA was selected as best LSC marker
in 63%, followed by Combi (183%), CD123 (133%) and
CD33 (50%). Marker CD44 was never selected.
Repeat analyses by individual operators are evaluated in a
select set of samples and is shown in Figure S6 and corre-
sponding Table SVIII. The variance introduced by repeated
analyses is minor, and had no effect on the outcome (i.e.
LSClow remained LSClow, LSChigh remained LSChigh).
Fig 2. Central site inter-instrument processing. Multiple samples with similar processing were measured across multiple flow cytometric instru-
ments (A) or platforms (B). (A) Training sample 1 was measured on BD FACSCanto II (I) and BD LSRFortessa (II). FACS plots of complete
blasts (top row) and CD34+ blasts (bottom row). CD33 and CD34 were exchanged in the channel (see Table S3) for standardisation within the
coordinating institute. (B) A diagnostic AML sample was measured on BD FACSCanto II (I) and BC Gallios EX (II). FACS plots for complete
blast population (top row) and CD34+ blast population (bottom row). (C) LSC percentages (dots) and lymphocyte percentages (diamonds) anal-
ysed in samples measured on BD LSRFortessa (black) and BC Gallios EX (red), compared to BD FACSCanto II. 05 log error is depicted as diag-
onal lines. 003% clinical stem cell cut-off depicted as dotted lines. Pearson correlation coefficients between BC Gallios EX and BD FACSCanto II,
and BD LSRFortessa and BD FACSCanto II were r = 100, P =< 0001 and r = 091, P =< 00001 respectively. Grey: (CD34+) population; Red:
LSC; Green: HSC.
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Additional FCS files generated at central site with analysis by
local sites. LSC analyses of the local sites were evaluated in
the same set of ten FSC files (Figure S5B). Participating cen-
tres were unanimously able to distinguish LSChigh samples
V7, V8 and V10, but LSC percentages Table I and selected
markers differed (Table SVII). Sample V5 was identified in
6/7 laboratories as LSChigh, but identified as LSClow in one
participating laboratory with 0029% (nevertheless very close
to the cut-off of 003%). All results in LSChigh patients were
within 05 log error Fig 4, which was identified as accept-
able error (see Materials and methods above). There was a
high correlation in detected LSC burden (mean r = 0999,
range 0998–1000, P < 0001) between participating centres
and the central site. In analyses of the local sites, CD45RA
was selected as best marker in most samples (386%), fol-
lowed by Combi (271%). CD44 was selected as best marker
in 171%, while never being selected by researchers from the
central site. While none of the researchers from the central
site selected the same marker for all samples, three partici-
pating institutes did.
Clinical implications
Implementation of the assay has important clinical implica-
tions as it allows the identification of patients who have a
distinctly different prognosis, and could therefore be added
to future risk classification. Correct characterisation of
patients with a significant poor outcome (LSChigh) and
patients with a significant better outcome (i.e. CD34–18) was
evaluated. The 14 samples analysed within this study
included four patients with high LSC load and two CD34–
patients. Three patients were correctly identified as LSChigh
in all analyses. The remaining sample were correctly cate-
gorised in 12/13 analyses. The two CD34– patients were
recognised as LSClow in all analyses, but only researchers
from the coordinating institute noted that these patients were
Fig 3. Results of central site and local sites on initial samples. Results of analysis of FCS files generated at central site by six researchers from cen-
tral site (black), results of FCS files generated at local sites with analysis by one researcher from central site (grey) and results of FCS files gener-
ated at local sites with analysis from local site (blue) on samples T1–T4. All individual results are shown as the percentage of leukaemic stem
cells of the complete white blood cell compartment. Laboratories are specified using different symbols, showing that differences in LSC percent-
ages is not consistently explained by one laboratory. Axes run from 0000% to 0030% (clinical relevant cut-off) for sample T1 and T2, and
0000–0003% for samples T3 and T4. CD44 is not depicted due to high variance (shown in Figure S3).
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CD34–. It is important to note that the participating centres
were not specifically asked for this conclusion. Fig 4C shows
a higher variation in samples below the clinical 003% cut-
off, as is to be expected. However, the clinical value of the
exact frequency of LSC at time of the diagnosis is not thor-
oughly established and is possibly obscured due to higher
intra- and inter-laboratory variability. In summary, the data
reveal that the current dichotomisation between LSChigh and
LSClow is more robust, and should therefore be adopted.
Discussion
Identification of patients with a high LSC load at time of
diagnosis, allows identification of patients with poor disease
outcome very early in the disease course.6,16 Similarly, identi-
fication of patients who lack aberrant leukaemic CD34+
(stem) cells allows identification of patients with a distinct
and better prognosis before the response of therapy can be
perceived.18 While the contribution of CD34+CD38– LSC to
poor disease outcome is demonstrated in several studies,19-21
LSC measurements are not clinically implemented because of
the seemingly complex process which requires specific experi-
ence and standardisation in the laboratories involved. Among
eight institutes, this study shows that the one-tube LSC assayT
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Fig 4. Results of central site and local sites on validation FCS files.
Ten representative diagnostic AML samples were selected and corre-
sponding flow cytometry files were sent to six researchers from the
central site and seven participating centres for analysis. Results were
reported back as the leukaemic stem cell percentage analysed by the
most reliable stem cell marker (or markers). Results reported by one
researcher from the central site compared to LSC percentages
reported by all other participants (researchers from the central site in
black, participating laboratories in blue). Previously determined (and
validated) cut-off of 003% is shown as a dotted line. Results above
the clinical validated cut-off fall within 05 log error, shown as grey
diagonal lines. Lower percentages fall outside 05 log error but are
clinically irrelevant.
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is highly reproducible between several large-flow cytometry
AML centres in both Europe and the United States after a
relatively simple training.
Sophisticated 8–10 colour flow cytometry is at the basis of
the diagnosis, characterisation and monitoring of haemato-
logical malignancies. Correct implementation of the tech-
nique and standardisation in its applications is of high
importance and several guidelines to achieve this have
recently been published.22,23 In this study, we demonstrate
that harmonisation between flow-cytometers is required for
comparable results. Here, the use of BD’s FC beads or setup
according to Euroflow protocol was adequate to result in
comparable measurements as percentages of lymphocytes,
blasts, CD34+ blasts, CD34+ CD38dim and CD34+CD38–
fractions were decidedly comparable among all institutes
(data not shown).
A defined gating strategy is essential for laboratories aspir-
ing to incorporate any flow cytometric assessment. To high-
light the effectiveness of our gating strategy, our training
focused on samples low in LSC frequency (three LSClow, one
CD34–), since analyses of low-frequent cell populations is
sensitive to errors. Nonetheless, limited feedback from expe-
rienced researchers was sufficient to train new researchers to
gate according to protocol and achieve a high degree of com-
parison with those results found by experienced researchers.
During the training phase, a number of critical steps in the
gating strategy were elucidated and are emphasised in this
article.
The development of a standardised antibody panel for
LSC detection14 helps to aim at standardisation. This tube
simplifies LSC assessment in routine AML-flow cytometry
work-up, as well as limiting the costs and the number of cells
needed. While the LSC tube consists of the best (most dis-
criminating, high negative predictive value and most sensi-
tive) markers for identification of LSC, some were preferred
over others. Markers CD45RA and Combi often show dis-
tinct separation between HSC and LSC as two separate ‘tails’
within the CD34+CD38– fraction. CD44 is used as a marker
for LSC14 based on overexpression of CD44 compared to
expression on normal haematopoietic (stem) cells,24 but cor-
rect identification of normal-high expression versus overex-
pression is difficult when only one ‘tail’ is present. For
specific purposes, exclusion of CD44 could be suggested to
allow incorporation of additional antibodies.
The training in analysis was confirmed by ten representa-
tive diagnostic AML samples, ranging from high levels of
LSC to absence of LSC, mimicking the clinical setting. As
expected, a high degree of correlation is found in samples
with higher frequencies of LSCs, in contrast to samples with
low frequencies. Previously, a cut-off of 003% was identified
as clinically and prognostically relevant.6,16 In our validation,
five samples with percentages proximal to this cut-off were
correctly classified in 4/5 cases, with the remaining sample
being misclassified as LSClow by one institute (with 0029%
just below cut-off). Analysis of the exact percentage of LSC
below the 003% cut-off is prone to higher variation, but
critical analysis of LSClow patients is crucial for the identifica-
tion of CD34– patients, associated with an overall good prog-
nosis.16,18 Further research should be undertaken to evaluate
whether CD34– patients are correctly identified and discrimi-
nated from LSClow patients.
Although addition of LSC measurements at diagnosis may
lead to further improvement of risk group stratification,
post-induction MRD measurements are valuable for guiding
post-remission strategies.25 MRD in AML is a rapidly evolv-
ing area with fast developments in designs and approaches.
While the introduction of next-generation sequencing MRD
detection certainly holds promise for the future, the combi-
nation with flow cytometry showed that both techniques
contributed independently to the prognostic value of the
patient cohort.2 Combining flow cytometry MRD measure-
ments with post-induction LSC measurements improved the
prognostic classification further.16 Since LSC in MRD situa-
tions are rare events, correct gating of LSCs, but also mea-
surement of sufficient WBCs is critical. The possibility and
practicability of LSC MRD measurements are not yet
described in this manuscript and should be explored as part
of the proceedings of this multicentre international group.
Current limitations of this study include the selection of a
restricted set of patient samples which conceivably does not
cover the complete cellular heterogeneity seen within the
AML population. It could therefore be argued that the
implementation of the assay in centres needs to be evaluated
in prospective multicentre studies. Furthermore, all samples
measured were cryopreserved mononuclear cells. Ideally,
fresh samples would be first measured at the coordinating
institute, deemed suited for the training and then immedi-
ately sent to the participating centres and measured. This
was considered impractical due to introducing more variabil-
ity because of poorer viability. As the effect of different sam-
ple processing could therefore not be analysed extensively,
the use of a standardised protocol is therefore warranted.15,26
In summary, we show that the one-tube LSC assay is
highly reproducible for many different FC experienced labo-
ratories after a relatively simple training. Since the tube is
useful for finding almost all CD34+CD38– stem cells and
requires limited samples, it can be implemented in clinical
studies. The high concordance between different laboratories
is particularly valuable for use in multicentre studies. These
results, together with the high prognostic impact of the LSC
load at diagnosis in AML patients render the one-tube LSC
assessment a good marker for future risk classification.
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